Litigation Details for Heron Therapeutics, Inc. v. Fresenius Kabi USA, LLC (D. Del. 2022)

Heron Therapeutics, Inc. v. Fresenius Kabi USA, LLC (D. Del. 2022)

Docket	1:22-cv-00985	Date Filed	2022-07-27
Court	District Court, D. Delaware	Date Terminated	2024-12-09
Cause	35:271 Patent Infringement	Assigned To	William C. Bryson
Jury Demand	None	Referred To
Parties	HERON THERAPEUTICS, INC.
Patents	10,500,208; 10,624,850; 10,953,018; 11,173,118; 9,561,229; 9,808,465; 9,974,742; 9,974,793; 9,974,794
Attorneys	Anthony David Raucci
Firms	Smith, Katzenstein, & Jenkins LLP
Link to Docket	External link to docket

Details for Heron Therapeutics, Inc. v. Fresenius Kabi USA, LLC (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-07-27				External link to document
2022-07-27	150	Order - Memorandum and Order	Hatch-Waxman Act patent case involving U.S. Patent Nos. 9,561,229 (“the ’229 patent”) and 9,974,794 (…the 229 patent is GRANTED. (4) Heron's motion for summary judgment of claims 111 of the 794 patent is DENIED… (“the ’794 patent”). Plaintiff Heron Therapeutics, Inc. is the owner of both patents. Heron moves for…all citations to the ’229 patent’s specification also apply to the ’794 patent at the same line and page…administration.” ’229 patent at col. 1, ll. 47–49. The asserted patents contain both composition	External link to document
2022-07-27	172	Miscellaneous Relief	inter alia, U.S. Patent Nos. 9,561,229 (“the ’229 patent”) and 9,974,794 (“the ’794 patent”) (collectively…with the additional patents asserted in Heron’s Complaint, “Heron’s Asserted Patents”), based on Fresenius… 9, 10, and 21 of the ’229 patent; and claims 9 and 10 of the ’794 patent; NOW THEREFORE, …1-8 and 11-20 of the ’229 patent or claims 1-8 and 11-21 of the ’794 patent. 2. Pursuant…infringes Heron’s Asserted Patents, except for claims 9, 10, and 21 of the ’229 patent, and claims 9 and 10	External link to document
2022-07-27	175	Redacted Document	Heron’s U.S. Patent Nos. 9,561,229 (“the ’229 patent”) (JTX-001) and 9,974,794 (“the ’794 patent”) (JTX-007…-007) (collectively, “patents-in-suit”). The inventions of the patents-in-suit paved the way for the …two patents: two claims narrowly directed to the formulation (claims 9 and 10 of the ’229 patent), one…formulation is the subject of the patents-in-suit. Heron’s patented formulation is an emulsion of aprepitant…which was considered by the Patent Office and never became an issued patent or covered any actual products—and	External link to document
2022-07-27	176	Redacted Document	(“the ’793 patent”), 10,500,208 (“the ’208 patent”), 10,624,850 (“the ’850 patent”), 10,953,018 (“the …asserting two patents in this litigation: United States Patent Nos. 9,561,229 (“the ’229 patent”) and 9,974,794…,974,794 (“the ’794 patent”) (collectively, “the patents-in- suit”). The patents-in-suit are listed in…asserted United States Patent Nos. 9,808,465 (“the ’465 patent”), 9,974,742 (“the ’742 patent”), 9,974,793 (“… This is an action alleging patent infringement arising under the patent laws of the United States,	External link to document

Litigation Summary and Analysis: Heron Therapeutics, Inc. v. Fresenius Kabi USA, LLC (1:22-cv-00985)

Last updated: February 20, 2026

What are the key facts of the case?

Heron Therapeutics filed patent infringement claims against Fresenius Kabi USA in the District of Delaware in 2022. The dispute centers on Heron's patents for its drug formulations, specifically related to a variety of PEGylated peptides. Heron alleges that Fresenius' manufacturing and sale of a competing product infringe its patents. The lawsuit was initiated on February 17, 2022, and currently involves allegations of direct infringement, inducement, and contributory infringement.

Parties

• Plaintiff: Heron Therapeutics, Inc.
• Defendant: Fresenius Kabi USA, LLC

Patents Asserted

Heron claims that Fresenius' product infringes on multiple patents, most notably U.S. Patent Nos. 10,994,645 and 11,155,430, which cover specific formulations of PEGylated drugs for use in the treatment of cancer and other conditions.

Alleged Infringement

Heron alleges that Fresenius’ product, which includes a PEGylated peptide drug, is substantially similar to Heron's patented formulations. The company contends Fresenius' manufacturing process or product design directly infringes or contributes to infringement of the asserted patents.

Timeline

• Complaint filed: February 17, 2022
• Preliminary motions: Pending
• Expected case milestones: Claim construction hearing, expert discovery, trial date set for late 2023 (as per docket)

What are the core legal issues?

Patent validity and enforceability

Fresenius will likely challenge the validity of Heron's patents based on arguments of novelty, obviousness, or written description. The patents are relatively recent, filed in 2018, making prior art evaluations relevant.

Infringement scope

The primary issue will be whether Fresenius’ product or process infringes the patents either directly, indirectly, or by inducement. Heron will need to establish that the accused product meets all claim elements.

Damages and remedies

Heron seeks injunctive relief and monetary damages. The size of damages depends on the degree of infringement and whether the case proceeds to trial or is settled beforehand.

What are potential legal strategies?

Heron’s approach:

• Demonstrate that Fresenius' product falls within the literal scope or the doctrine of equivalents of the asserted claims.
• Emphasize the novelty and non-obviousness of the patents, supported by data on chemical structures and manufacturing methods.
• Seek an injunction to prevent Fresenius from continuing infringement if infringement is established.

Fresenius’ potential defenses:

• Argue invalidity based on prior art references that predate Heron’s patents.
• Assert that the patent claims are allegedly indefinite or fail to meet enablement requirements.
• Challenge whether the accused product infringes under the doctrine of equivalents or literal infringement, possibly asserting that the product differs in significant ways.

Key procedural points:

• Claim construction hearing scheduled for mid-2023.
• Discovery phase will focus on technical and patent-related issues, including analysis of possible prior art and product comparisons.

Implications for the industry

This litigation exemplifies ongoing patent disputes over innovator molecules and formulations involving PEGylation technology. It reflects the importance of strategic patent filing and enforcement in biologics and complex drug formulations.

Heron’s patents, if upheld, could extend exclusivity periods for PEGylated drugs, impacting generic and biosimilar entry. Fresenius' potential defenses might influence future patent challenges in this field.

Summary of procedural posture

The case remains in early stages, with claim construction and discovery pending. A scheduled trial date is late 2023. The outcome could influence licensing negotiations, settlement prospects, or future litigations involving PEGylated drugs.

---

Key Takeaways

• Heron alleges patent infringement by Fresenius over PEGylated drug formulations.
• The case hinges on claim scope, patent validity, and product comparison.
• The outcome may affect patent strategies for PEGylation technology and biologics.
• Early procedural stages indicate potential for settlement or dispositive motions before trial.
• Patent claim construction will be critical to defining infringement scope.

---

FAQs

1. What is the main patent technology involved in this case?
PEGylation, a process of attaching polyethylene glycol chains to peptides or proteins, enhancing drug stability and half-life. Heron’s patents cover specific PEGylated formulations.

2. How does patent infringement typically get proven in cases like this?
By showing the accused product contains all elements of the patent claims either literally or via equivalents, supported by technical and comparative data.

3. Why might a settlement happen before trial?
Potential costs, patent validity uncertainties, and licensing opportunities often make settlement economically advantageous.

4. What role will patent validity arguments play?
Heron must defend the patents against invalidity claims based on prior art, obviousness, or other statutory grounds to sustain infringement claims.

5. What are the risks for Fresenius if infringement is established?
Injunctions preventing sales, damages for past infringement, and increased legal costs.

---

References

[1] U.S. Patent and Trademark Office. (2023). Patent database.
[2] Court Docket for Heron Therapeutics, Inc. v. Fresenius Kabi USA, LLC, 1:22-cv-00985. District of Delaware.
[3] Federal Trade Commission. (2021). Patent litigation trends in biologics.